digoxin and Infant--Newborn--Diseases

Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biological Availability; Cardiopulmonary Bypass; Child; Child, Preschool; Digoxin; Drug Interactions; Female; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Intestinal Absorption; Kinetics; Maternal-Fetal Exchange; Pregnancy

Topics: Abnormalities, Drug-Induced; Analgesics; Bupivacaine; Carbamazepine; Chloramphenicol; Diazepam; Digoxin; Female; Fetus; Furosemide; Gentamicins; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; Lidocaine; Penicillins; Phenobarbital; Phenytoin; Pregnancy; Pregnancy Complications; Tetracycline; Theophylline

Digoxin rapidly crosses the placenta and reaches equilibrium, with maternal and fetal sera having equal concentrations. Virtually nothing is known about the effects of transplacentally administered digoxin on the fetus. Toxicity has been reported in the fetus of a woman ingesting a huge overdose of digitoxin; the same result would be anticipated with digoxin poisoning. Serum levels in pregnant women receiving the standard dose of 0.25 mg tend to be subnormal and certain patients may require a small increase in dose during the last trimester. While the full-term neonate appears to tolerate relatively high doses and the resultant high serum levels, there is no compelling evidence that such doses are necessary or even useful. Since toxicity can and does occur in neonates, especially during administration of loading (digitalizing) doses, it is recommended that maintenance doses of 0.01 mg per kg per day be used routinely. If the full inotropic effect is needed immediately, a loading dose of 0.03 mg per kg may be employed. Maintenance therapy is then begun on the following day. Without a loading dose cumulation occurs for about 3 days; after 5 or so days, serum levels will equal those found after use of a loading dose followed by maintenance therapy. Results of a single study suggest that the daily dose should be divided and given every 12 hours. After about 1 week of therapy, the serum level should be determined and the dose modified to maintain a serum level of 1 to 2 ng per ml. If the therapeutic effect is less than desired, a cautions increase in dose to as high as 0.02 mg per kg per day or to that dose which produces serum levels up to 3 ng per ml can be tried. Certain infants appear to tolerate serum levels of 3.5 to 4 ng per ml but such infants must be closely monitored. There are no data which indicate that a greater inotropic response will occur at these high serum levels, though this point has not been definitively investigated, and is the highest priority question for research. The intramuscular route should be researved for the unusual situation. Vomiting should be considered an early sign of toxicity and may act as a "safety valve." When adminstered in solution (as in the elixir or solution for intravenous use), oral digoxin is rapidly absorbed an an inotropic response is found within minutes, reaching a peak within hours, so that little is gained by parenteral administration. If an inotropic effect is urgently needed, intravenous administration o

Topics: Animals; Digitalis Glycosides; Digoxin; Female; Fetus; Heart; Heart Diseases; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exchange; Pregnancy

We have measured the plasma concentrations in sick neonates and infants being administered digoxin by a safer regimen. In the presence of normal renal function the plasma concentrations appear to be satisfactory.

Topics: Administration, Oral; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intramuscular

The authors report two cases of foetal supraventricular tachycardia in healthy hearts with 1/1 atrioventricular conduction which turned out to be atrial tachycardias in the postnatal period. The first foetus had permanent tachycardia at 190/minute at 34 weeks' amenorrhea with left ventricular dysfunction at 36 weeks. In the postnatal period, treatment with digoxine and amiodarone restored sinus rhythm and normal left ventricular function. Permanent foetal tachycardia, even at a rate of less than 200 beats/minute, should suggest an arrhythmia and may lead to left ventricular dysfunction in utero. The other foetus had an aneurysm of the foramen ovale with paroxysmal tachycardias at 220/minute without cardiac dysfunction. A Holter at 1 month showed paroxysmalatrial tachycardia. Postnatal rhythm monitoring is necessary in paroxysmal foetus tachycardia, especially with prenatal aneurysm of the foramen ovale.

Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Electrocardiography; Electrocardiography, Ambulatory; Female; Fetal Diseases; Heart Aneurysm; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Pregnancy; Prenatal Diagnosis; Tachycardia, Ectopic Atrial

There are a lot of publications about fetal arrhythmia in singletons, but up to now there are no published data about fetal arrhythmia in multiple pregnancies. In the present study a case history of fetal and neonatal arrhythmia in one of twins from two mothers treated with betamimetic agents due to imminent preterm labor is reported and discussed. A first case with fetal bradycardia due to complete A-V block had congenital cordis abnormalities (VSD and PFO). The second case with prenatal detected extrasystoles had normal heart anatomy. Digoxin was administered to the mother, in the aim to treat fetal arrhythmia without success, because the baby had postnatal bradycardia. After hospitalisation in Cardiology Department the described cases were successfully treated. In both cases the second twins were without neonatal arrhythmia and with no structural heart abnormalities. We summarise that in situation of detection fetal arrhythmia the complexity of the problems experienced may warrant early referral to a tertiary centre where the overall management of the mother, fetus and neonate, may be undertaken.

Topics: Arrhythmias, Cardiac; Bradycardia; Cardiac Complexes, Premature; Digoxin; Diseases in Twins; Female; Fetal Diseases; Fetal Heart; Gestational Age; Heart Block; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Obstetric Labor, Premature; Pregnancy; Twins; Ultrasonography, Prenatal

Topics: Canada; Digoxin; Epidemiologic Methods; Forensic Medicine; Homicide; Humans; Infant, Newborn; Infant, Newborn, Diseases; Intensive Care Units, Neonatal; Nursing Staff, Hospital; Space-Time Clustering

Topics: Digoxin; Electrocardiography; Female; Fetal Diseases; Fetal Distress; Humans; Infant, Newborn; Infant, Newborn, Diseases; Pregnancy; Tachycardia; Tachycardia, Paroxysmal

Digoxin serum concentrations were measured by a routine radioimmunoassay in 30 neonates not receiving digoxin; nonetheless, digoxin levels were between 0.17 nM and 1.64nM (means = 0.64nM +/- 0.27 nM). There was a negative correlation between gestational age and concentration of an endogenous digoxin-like substance (EDLS). Neonates less than or equal to 32 wk gestational age had higher levels of EDLS than neonates greater than 32 wk old. EDLS concentrations were compared in 22 mothers and their 24 offspring and were higher in all newborn infants (0.34nM +/- 0.09nM and 0.15nM +/- 0.08nM). EDLS was shown to inhibit Na+-K+-adenosinetriphosphatase activity by measurement of 86Rb uptake in erythrocytes exposed to sera samples from 30 infants in the study. EDLS levels greater than 0.6 ng/ml were associated with lesser 86Rb uptake. Simulation kinetics suggest that the presence of 0.6nM EDLS would lengthen the digoxin t1/2 by 64%, reduce the volume of distribution by 23%, and lower clearance by 53% if the peak "true" digoxin level were 2 ng/ml. EDLS concentrations of 1.5 ng/ml would increase the t1/2 by 207% while reducing the volume of distribution by 43% and clearance by 81%. These considerations cast serious doubts on the validity of currently accepted digoxin kinetics and dosing in preterm infants.

Topics: Birth Weight; Blood Proteins; Cardenolides; Digoxin; Female; Fetal Blood; Gestational Age; Half-Life; Humans; Infant, Newborn; Infant, Newborn, Diseases; Kinetics; Prospective Studies; Radioimmunoassay; Radioisotopes; Rubidium; Saponins

Topics: Arrhythmias, Cardiac; Digoxin; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male

Topics: Brain Chemistry; Digoxin; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Intestines; Kidney; Muscles; Myocardium; Radioimmunoassay

Topics: Arrhythmias, Cardiac; Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Propranolol

Eighteen neonates in heart failure were investigated to assess whether high or low serum digoxin levels had differing effects on left ventricular function as determined by systolic time intervals obtained by echocardiography. Nine patients had digoxin levels of 1.99 +/- 0.35 ng/ml (group 1). Nine others had levels of 3.62 +/- 0.95 ng/ml (group 2). Systolic time intervals were obtained by echocardiography before and at 5 days after digoxin and correlated with serum levels. The heart rate, preejection period (PEP), left ventricular ejection time (LVET), electromechanical systole (QS2) and the PEP/LVET ratio were measured. LVET and electromechanical systole were indexed. These measurements were analyzed and the two groups were compared using Student's t test. The clinical improvement in both groups was similar and no difference in ECG changes were noted. Therapy with digoxin produced changes in heart rate and systolic time intervals in both groups. Both showed significant shortening of electromechanical systole index; group 1 significantly shortened the LVET index and PEP/LVET ratio, whereas group 2 significantly shortened the PEP. Statistical analysis comparing the two groups showed no difference between them. Digoxin produces measurable changes in the indices of left ventricular function. The magnitude of these changes suggests no therapeutic advantage to the higher levels.

Topics: Digoxin; Echocardiography; Electrocardiography; Heart Diseases; Heart Ventricles; Humans; Infant, Newborn; Infant, Newborn, Diseases; Myocardial Contraction; Systole

Topics: Digoxin; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Infant, Newborn, Diseases

A newborn baby shows atrial tachycardia and gets into cardiac failure by atrial fibrillation at 12 weeks of age. With digoxin and chinidin spontaneous conversion to multifocal atrial tachycardia occurs. Treatment with additional propranolol leads to atrial fibrillation and paroxysmal atrial tachycardia with block. When chinidin was discontinued atrial flutter occurred. With a maintenance therapy with digoxin and chinidin the baby remained asymptomatic, and sinusrhythm occurred at 6 months of age. At 9 months chinidin was discontinued. At 14 months of age, the child is well and in sinusrhythm with a maintenance digoxin therapy. This seems to be the third described case of multifocal atrial tachycardia in infancy.

Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electrocardiography; Heart Rate; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Male; Propranolol; Quinidine; Tachycardia; Tachycardia, Paroxysmal

Topics: Atrial Flutter; Digoxin; Electrocardiography; Humans; Infant, Newborn; Infant, Newborn, Diseases

23 cases of paroxysmal tachycardia in infancy and childhood (22 cases of supraventricular and 1 case of ventricular paroxysmal tachycardia) are reported. Clinical problems of 13 infants aged 1 day to 6 months are compared with those of 10 children and discussed. A primary disease e.g. congenital heart disease, myocarditis was observed in 8 cases and WPW-syndrome in 4 cases. Owing to the threatening cardiac failure especially in infancy a special attention should be taken to the immediately diagnosis. Treatment and prevention are discussed.

Topics: Child; Child, Preschool; Digoxin; Electrocardiography; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Male; Radiography; Tachycardia, Paroxysmal; Wolff-Parkinson-White Syndrome

During childhood digitalis glycosides are most frequently used during the newborn period. Within two years, we found evidence of digoxin intoxication in eight newborns. This was suspected when specific electrocardiographic signs developed under digoxin treatment and disappeared either after discontinuation of digoxin alone, or in combination with specific treatment. These eight newborns had plasma digoxin concentrations of 5 ng/ml or more, while the concentrations in unaffected newborns averaged 2.4 ng/ml (premature newborns) and 2.2 ng/ml, (mature newborns). The clinical and pathophysiological features of digoxin intoxication specific to the newborn period are discussed. Despite certain limitations it seems reasonable to check plasma digoxin concentrations during the newborn period, since clinical and electrocardiographic manifestations of a digoxin intoxication are frequently unspecific at this age. A digoxin intoxication is very likely with plasma digoxin concentrations of 5 ng/ml or more, but unlikely with concentrations below 3 ng/ml.

Topics: Digoxin; Electrocardiography; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature

Serum digoxin levels were measured in 53 neonates and infants receiving 18-22 microgram/kg/day (high dose) oral maintenance digoxin, and 44 neonates, infants and children receiving less than 18 microgram/kg/day (low dose) oral maintenance digoxin. In both groups, patients under four months of age had significantly higher serum digoxin levels than older patients, in the high dose group 2.6 ng/ml compared with 1.4 ng/ml and in the low dose group 2.2 ng/ml compared with 1.0 ng/ml. Correlation between digoxin dosage and serum level was weak and unaffected by blood urea level. Only two patients in the entire series showed toxic manifestations. Sixteen patients had serum digoxin levels measured before and after corrective cardiac surgery while receiving comparable dosages of digoxin. Despite lower serum digoxin levels postoperatively pulse rates fell significantly, illustrating the influence of changing haemodynamic status on the inter-relationships of digoxin dosage, serum levels and clinical response. Recommended dosage regimens are outlined.

Topics: Adolescent; Age Factors; Child; Child, Preschool; Depression, Chemical; Digoxin; Heart Diseases; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Pulse

Serum concentrations and half-life times of digoxin were determined in ten mature and nine premature newborns. Median serum digoxin concentration was 2.3 ng/ml (1.2 to 3.5 ng/ml) in mature newborns and 2.4 ng/ml (1.5 to 4.5 ng/ml) in premature newborns. Median serum digoxin half-life was 35 hours (17 to 52 hours) in mature newborns and 57 hours (38 to 88 hours) in premature newborns. The difference in serum digoxin half-life between the two groups is statistically significant. The relatively long serum digoxin half-life in premature newborns is probably due to immature renal function in this group. The data emphasize the need for cautious digoxin administration, especially in premature infants.

Topics: Digoxin; Half-Life; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases

A case of atrioventricular reciprocal rhythm and chronic reciprocating tachycardia in a newborn infant is presented. Electrophysiological studies suggest that these rhythm disturbances are related to the presence of a right-sided atrioventricular accessory pathway capable only of retrograde conduction (concealed Wolff-Parkinson-White syndrome). The technique of recording the sequence of atrial activation during the tachycardia is described and its clinical importance emphasised.

Topics: Cardiac Catheterization; Digoxin; Electrophysiology; Heart Block; Heart Conduction System; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Propranolol; Tachycardia; Wolff-Parkinson-White Syndrome

Serum digoxin values were determined in a newborn infant with severe heart failure and renal failure. The half-life of digoxin in the serum appeared to change, possibly the result of prolonged distribution and/or absorption owing to circulatory insufficiency, or to the accumulation of cross-reacting metabolites of digoxin in the serum. No clinical toxicity was apparent, and no cardiac arrhythmia was observed. The need for monitoring serum digoxin concentration and clinical effect in newborn infants is emphasized.

Topics: Anuria; Aortic Coarctation; Creatinine; Digoxin; Half-Life; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male

Topics: Atrial Flutter; Digoxin; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Quinidine

Ten infants who had paroxysmal atrial tachycardia in utero or at birth are reported. Because of apparent fetal distress, caesarean section was performed in 4 cases and labour was induced in 1. Birthweight was generally large for gestational age. Severe ascites and hydrops at birth were manifestations of cardiac failure. Atrial flutter was recorded in 4 infants and supraventricular tachycardia in 5. The WoLff-Parkinson-White syndrome became evident later in 2. Digoxin was given to all 10 infants, and cardioversion was required and was effective in 4. Known recurrences in childhood have occurred in only 1 patient. Congenital atrial tachyarrhythmias may be commoner than generally believed, and fetal electrocardiography may help to avoid unnecessary termination of pregnancy. Blood sugar determinations are important, since neonatal hypoglycaemia was found. Cardioversion should be performed promptly in severely ill infants or if there is no response to digoxin. Care is required to avoid digoxin toxicity.

Topics: Birth Weight; Digoxin; Female; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Tachycardia, Paroxysmal

Topics: Bed Rest; Child, Preschool; Digoxin; Diuretics; Heart Failure; Humans; Hypnotics and Sedatives; Infant; Infant, Newborn; Infant, Newborn, Diseases

Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Bradycardia; Cardiovascular Diseases; Digoxin; Emergencies; Epinephrine; Female; Fetal Diseases; Fetal Heart; Haplorhini; Heart Failure; Heart Rate; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Newborn, Diseases; Isoproterenol; Lidocaine; Pregnancy; Radiography; Resuscitation; Transposition of Great Vessels

A critically ill infant with paroxysmal supraventricular tachycardia and hydrops fetalis responded well to aggressive management. Care must be taken to avoid digitalis toxicity. Procaine amide or quinidine are effective alternate therapies.

Topics: Digoxin; Edema; Electrocardiography; Female; Fetal Diseases; Furosemide; Heart Ventricles; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Positive-Pressure Respiration; Pregnancy; Procainamide; Tachycardia, Paroxysmal; Water

Topics: Blood Gas Analysis; Cardiac Catheterization; Cyanosis; Digoxin; Electrocardiography; Female; Fetal Heart; Heart Auscultation; Heart Defects, Congenital; Hematocrit; Hemodynamics; Humans; Hypoxia; Infant, Newborn; Infant, Newborn, Diseases; Oxygen; Oxygen Inhalation Therapy; Physical Examination; Pregnancy; Primary Health Care; Pulse

Two cases of congenital atrial flutter, one of which was documented electrocardiographically before birth, are reported. In both patients sinus rhythm was restored with digoxin treatment; in one patient the transition was preceded by various arrhythmias. No cardiac malformation was found in either case, and no materal disease occurred during pregnancy. Both mothers had received medication during pregnancy, but its role as a causative factor is questionable.

Topics: Atrial Flutter; Chloramphenicol; Chloroquine; Digoxin; Electrocardiography; Female; Fetal Diseases; Fetal Heart; Follow-Up Studies; Humans; Infant, Newborn; Infant, Newborn, Diseases; Malaria; Pregnancy; Pregnancy Complications, Infectious

The bioavailability of digoxin in solution was studied in 4 newbron infants with heart failure. Serum digoxin concentrations were determined by radioimmunoassay using 125I. Bioavailability was estimated by camparison of the areas under the 8-h serum concentration curves (8-h AUC) after intravenous and oral administration of the glycoside. After oral administration of digoxin (1/4 of the digitalizing dose, 0.05 mg/kg bw), peak serum values of 2.3-4.4 ng/ml were reached within 30-90 min. After intravenous administration of the same amount of the glycoside, there was a rapid decrease in serum concentration during the first 2 h, and after about 4 h the serum concentration curves paralled those obtained after oral dosing. Based on within subject comparison of intravenous and oral 8-h AUC'S, the mean bioavailability of digoxin was estimated to be 72 per cent (range 52-79 per cent). It was concluded that digoxin in solution, given to infants with mild to moderate heart failure, is well absorbed and biologically available to the same extent as in adults.

Topics: Administration, Oral; Biological Availability; Digoxin; Female; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intravenous; Intestinal Absorption; Kinetics; Male; Radioimmunoassay

Topics: Adenosine Triphosphatases; Adolescent; Adult; Age Factors; Animals; Calcium; Cell Membrane; Child; Child, Preschool; Digitalis; Digitalis Glycosides; Digoxin; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Kidney Diseases; Myocardium; Ouabain; Plants, Medicinal; Plants, Toxic; Sodium; Tritium

Topics: Acute Disease; Biological Transport, Active; Digoxin; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infant, Premature, Diseases; Magnesium; Male; Phenytoin; Poisoning; Potassium; Respiratory Distress Syndrome, Newborn; Sodium; Vomiting

Topics: Acidosis; Angiocardiography; Cardiac Catheterization; Cineangiography; Diet Therapy; Digoxin; Diuretics; Electrocardiography; Heart Auscultation; Heart Defects, Congenital; Heart Diseases; Heart Failure; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoproterenol; Radiography, Thoracic; Respiration, Artificial

Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Atrial Flutter; Digoxin; Electric Countershock; Electrocardiography; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases

Topics: Digoxin; Edema; Heart Failure; Humans; Hypocalcemia; Hyponatremia; Infant, Newborn; Infant, Newborn, Diseases; Magnesium

Topics: Angiocardiography; Cardiac Catheterization; Coronary Circulation; Coronary Disease; Coronary Vessels; Cyanosis; Digoxin; Electrocardiography; Heart Failure; Heart Ventricles; Humans; Infant, Newborn; Infant, Newborn, Diseases; Oxygen Inhalation Therapy; Pulmonary Circulation; Respiratory Distress Syndrome, Newborn

Topics: Acidosis; Digitalis Glycosides; Digoxin; Electric Countershock; Electrocardiography; Female; Heart Block; Humans; Hypokalemia; Infant, Newborn; Infant, Newborn, Diseases; Male; Tachycardia, Paroxysmal

Topics: Ajmaline; Digoxin; Electrocardiography; Furosemide; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Phytotherapy; Plants, Medicinal; Potassium; Rauwolfia; Tachycardia, Paroxysmal; Wolff-Parkinson-White Syndrome

Topics: Cardiac Volume; Computers; Digoxin; Heart; Heart Defects, Congenital; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Phonocardiography

Topics: Age Factors; Atrial Flutter; Digoxin; Drug Resistance; Electric Countershock; Electrocardiography; Female; Heart Failure; Heart Septal Defects, Atrial; Heart Septal Defects, Ventricular; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intramuscular; Injections, Intravenous; Male; Pregnancy; Prognosis; Radiography; Sex Factors; Tachycardia

Topics: Asphyxia Neonatorum; Body Weight; Digoxin; Ductus Arteriosus, Patent; Female; Gestational Age; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Male; Organomercury Compounds; Respiratory Distress Syndrome, Newborn; Sex Factors

Topics: Atrial Flutter; Birth Weight; Body Weight; Digoxin; Edema; Electrocardiography; Female; Fetal Diseases; Fetal Heart; Furosemide; Heart Failure; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Pregnancy

Topics: Anti-Bacterial Agents; Anticoagulants; Aortic Coarctation; Bradycardia; Chlorothiazide; Diet, Sodium-Restricted; Digitalis Glycosides; Digitoxin; Digoxin; Drug Tolerance; Electrocardiography; Endocardial Fibroelastosis; Furosemide; Heart Block; Heart Defects, Congenital; Heart Failure; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Lanatosides; Myocarditis; Organomercury Compounds; Oxygen Inhalation Therapy; Potassium Chloride; Pulmonary Edema; Tachycardia; Tachycardia, Paroxysmal; Transposition of Great Vessels

Topics: Digoxin; Electrocardiography; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Tachycardia, Paroxysmal

Topics: Cesarean Section; Child; Digoxin; Electrocardiography; Female; Fetal Diseases; Fetal Heart; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Pregnancy; Tachycardia, Paroxysmal

Topics: Aminophylline; Aspirin; Atropine; Cardiomyopathies; Cataract; Child, Preschool; Chloramphenicol; Chlorothiazide; Conjunctivitis; Digoxin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Iatrogenic Disease; Infant; Infant, Newborn; Infant, Newborn, Diseases; Male; Ophthalmic Solutions; Pre-Eclampsia; Pregnancy; Purpura, Thrombocytopenic; Substance-Related Disorders; Suppositories

Topics: Adolescent; Digoxin; Female; Humans; Hyperthyroidism; Infant; Infant, Newborn; Infant, Newborn, Diseases; Long-Acting Thyroid Stimulator; Phenobarbital; Prednisolone; Tetracycline; Thyroiditis

Topics: Arrhythmias, Cardiac; Clinical Laboratory Techniques; Digoxin; Female; Goiter; Graves Disease; Hepatomegaly; Humans; Hyperthyroidism; Hypoprothrombinemias; Infant; Infant, Newborn; Infant, Newborn, Diseases; Iodides; Liver Diseases; Maternal-Fetal Exchange; Prednisolone; Pregnancy; Pregnancy Complications; Reserpine; Splenomegaly; Thrombocytopenia; Toxicology; Vitamin K

Topics: Adrenocorticotropic Hormone; Digoxin; Female; Genetics, Medical; Goiter; Graves Disease; Humans; Hyperthyroidism; Infant; Infant, Newborn; Infant, Newborn, Diseases; Pregnancy; Propylthiouracil; Thymus Gland; Thyroid Gland; Thyrotoxicosis